Evidence map›Paper›PMID 38322583›Full record

ArticleFrontiers in neurology2024

Digital assessment of speech in Huntington disease.

Adonay S Nunes, Meghan Pawlik, Ram Kinker Mishra, Emma Waddell, Madeleine Coffey, Christopher G Tarolli, Ruth B Schneider, E Ray Dorsey, Ashkan Vaziri, Jamie L Adams

Open access · goldAbstract read
In one paragraph

Article in Frontiers in neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Adonay S NunesBioSensics LLC, Newton, MA, United States.
Meghan PawlikCenter for Health + Technology, University of Rochester Medical Center, Rochester, NY, United States.
Ram Kinker MishraBioSensics LLC, Newton, MA, United States.
Emma WaddellWarren Alpert Medical School of Brown University, Providence, RI, United States.
Madeleine CoffeyDonald and Barbara Zucker School of Medicine, Uniondale, NY, United States.
Christopher G TarolliCenter for Health + Technology, University of Rochester Medical Center, Rochester, NY, United States.
Ruth B SchneiderCenter for Health + Technology, University of Rochester Medical Center, Rochester, NY, United States.
E Ray DorseyCenter for Health + Technology, University of Rochester Medical Center, Rochester, NY, United States.
Ashkan VaziriBioSensics LLC, Newton, MA, United States.
Jamie L AdamsCenter for Health + Technology, University of Rochester Medical Center, Rochester, NY, United States.
University of Rochester Medical Center · USBioSensics (United States) · USBrown University · USDonald & Barbara Zucker School of Medicine at Hofstra/Northwell · US

Funding

Wearable Sensors for Quantitative Assessment of Motor Impairment in Huntington's DiseaseR44NS103648 · NINDS · BIOSENSICS, LLC · PI NGUYEN, HUNG P. · 2017 to 2018
$2.5M
Wearable Sensor and Digital Technologies for Quantitative Assessment and Remote Monitoring of Symptoms in Myasthenia GravisR44NS122672 · NINDS · BIOSENSICS, LLC · PI Amanda Guidon, Ashkan Vaziri · 2022 to 2026
$2.5M
NINDS NIH HHS R44 NS103648NINDS NIH HHS R44 NS122672
6 · The paper itself

Abstract

Background: Speech changes are an early symptom of Huntington disease (HD) and may occur prior to other motor and cognitive symptoms. Assessment of HD commonly uses clinician-rated outcome measures, which can be limited by observer variability and episodic administration. Speech symptoms are well suited for evaluation by digital measures which can enable sensitive, frequent, passive, and remote administration. Methods: We collected audio recordings using an external microphone of 36 (18 HD, 7 prodromal HD, and 11 control) participants completing passage reading, counting forward, and counting backwards speech tasks. Motor and cognitive assessments were also administered. Features including pausing, pitch, and accuracy were automatically extracted from recordings using the BioDigit Speech software and compared between the three groups. Speech features were also analyzed by the Unified Huntington Disease Rating Scale (UHDRS) dysarthria score. Random forest machine learning models were implemented to predict clinical status and clinical scores from speech features. Results: Significant differences in pausing, intelligibility, and accuracy features were observed between HD, prodromal HD, and control groups for the passage reading task (e.g., Conclusion: Speech data have the potential to be a valuable digital measure of HD progression, and can also enable remote, frequent disease assessment in prodromal HD and HD. Clinical status and disease severity were predicted from extracted speech features using random forest machine learning models. Speech measurements could be leveraged as sensitive marker of clinical onset and disease progression in future clinical trials.

Indexed as

digital speech aidHuntington (disease)machine learingremote monitoringspeech assessment

Identifiers

PMID38322583
PMCPMC10844459
OpenAlexW4391144321

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.